glp-1 obesity drug updates The revolution: What UAB researchers are discovering about how these drugs work What is the pipeline for

5: e9590

It is between those who read the current evidence as sufficient justification for selective use and those who read it as insufficient justification for any routine adoption

The EY-Parthenon analysis projects usage to grow quickly in the coming 10 years to between 13% and 21% of US adults, a total market size of 30 million to 50 million people

87 Although these studies did include microbiota analysis, dietary intake is a major determinate of microbiota composition

Additionally, some novel GLP-1s hold promise for improved tolerability, as evidenced by Structure Therapeutics phase 2 data for GSBR-1290, which demonstrated encouraging results in terms of AEs and discontinuation rates